Items with tag "drug discovery"
News
Gilead and Galapagos enter into transformative research and development collaboration
Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment Gilead Gains Access to Galapagos’ Differentiated Drug Discovery Platform and Current and Future Pipeline O…
Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds
Ghent, Belgium, and Dresden, Germany - 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-pro…
Medulloblastoma orphan drug designation for Oncurious
Oncurious, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors, announces that the European Commission has confirmed the orphan…
John Berriman heads the Confo Therapeutics board
GPCR drug designer Confo Therapeutics has announced that John Berriman was appointed as Chairman of the Board. Berriman is a known biotech veteran and has served on the boards of many biotech comp…
Insights
Orphan CNS diseases receive attention with new Minoryx site in Belgium
The Spanish start-up Minoryx Therapeutics recently opened a subsidiary in Belgium to further their research on treatments for rare and orphan diseases. Co-founder and CEO Marc Martinell spoke to B…
How CRISPR/Cas9 is improving drug development using zebrafish
CRISPR/Cas9 came to the attention of scientists everywhere over five years ago. Ever since it hit the main stage, the gene editing technique has stayed in the spotlight, and for good reason. CRISP…
Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis
Galapagos (Belgium) and MorphoSys (Germany) recently announced that they have entered into an exclusive global license agreement with Novartis. The Swiss big-pharma partner has acquired the rights…
A world without disease: Janssen - Flanders.bio partner day 2018
A new vision was in the spotlight at the Flanders.bio - Janssen Pharmaceutica Partner Day this year. “A world without disease” was the slogan on everyone’s tongues as Janssen’s representatives and…
Fishing for answers: screening drug cardiotoxicity using zebrafish
Rodents have a well-established place in history as our most common animal models. Even the word lab-rat has become so commonplace it is a common lay-man term. However, could it be that another an…
UCB psoriasis drug approved for use in mothers
The UCB core drug CIMZIA® has just been approved by European Medicines Agency (EMA) for use in pregnant and breastfeeding mothers. The company has also sought to have CIMZIA approved for psoriasis…
WHO report ranks deadly diseases in need of drugs
The World Health Organization recently released a report outlining the imminent threat of antimicrobial-resistant diseases. In the midst of such doom and gloom, could a solution be found in our ow…
The Cystic Fibrosis association pushes research to the next level
Cystic fibrosis (CF) is a life-threatening disease, for which there is currently no treatment. There are some drugs on the market that, in certain cases, can alleviate the symptoms. In this articl…
AI improves patient care
Curing and caring for patients is a comprehensive process that requires research to discover new drugs, clinical trials to test the safety and efficacy of those drugs, and coaching and mentoring t…
Animal venom: a pharmacological goldmine
Until recently, not many people had heard of Alphabiotoxine—a rapidly developing Belgian company and the largest producer of diverse animal venoms in the world. All venoms hold a mixture of hundre…
VC Views
Are we spending too much money on cancer drugs?
November is classically the month where immunotherapy takes center stage, especially at the annual conference of the Society for Immunotherapy of Cancer (SITC, endearingly pronounced sitsie). Imm…
Bringing clinical trials into the home
Lowering the costs of drug development is more important than ever; with the increasing pressure on drug pricing and billions in funding poured into small biotechs, competition is fierce. While th…
